Trademark: 79237055
Status Date
Tuesday, April 14, 2020
Registration Number
6031354
Registration Date
Tuesday, April 14, 2020
Filing Date
Tuesday, April 24, 2018
Published for Opposition
Tuesday, January 28, 2020
5 Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome
Nov 20, 2021
New Representative At Ib Received
Sep 15, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Sep 15, 2021
Teas Change Of Correspondence Received
Sep 15, 2021
Teas Change Of Domestic Representatives Address
Sep 15, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Sep 15, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Sep 15, 2021
Teas Change Of Owner Address Received
Sep 5, 2020
Final Decision Transaction Processed By Ib
Aug 17, 2020
Final Disposition Notice Sent To Ib
Aug 17, 2020
Final Disposition Processed
Jul 14, 2020
Final Disposition Notice Created, To Be Sent To Ib
Apr 14, 2020
Registered-Principal Register
Jan 28, 2020
Official Gazette Publication Confirmation E-Mailed
Jan 28, 2020
Published For Opposition
Jan 24, 2020
Notification Processed By Ib
Jan 10, 2020
Notification Of Possible Opposition - Processed By Ib
Jan 8, 2020
Notification Of Possible Opposition Sent To Ib
Jan 8, 2020
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 8, 2020
Notification Of Notice Of Publication E-Mailed
Dec 25, 2019
Notification Of Possible Opposition Sent To Ib
Dec 25, 2019
Notification Of Possible Opposition Created, To Be Sent To Ib
Dec 23, 2019
Assigned To Lie
Dec 20, 2019
Approved For Pub - Principal Register
Dec 19, 2019
Examiner's Amendment Entered
Dec 19, 2019
Notification Of Examiners Amendment E-Mailed
Dec 19, 2019
Examiners Amendment E-Mailed
Dec 19, 2019
Examiners Amendment -Written
Jun 20, 2019
Notification Of Final Refusal Emailed
Jun 20, 2019
Final Refusal E-Mailed
Jun 20, 2019
Final Refusal Written
Mar 19, 2019
Teas/Email Correspondence Entered
Mar 18, 2019
Correspondence Received In Law Office
Mar 18, 2019
Teas Response To Office Action Received
Oct 7, 2018
Refusal Processed By Ib
Sep 19, 2018
Non-Final Action Mailed - Refusal Sent To Ib
Sep 18, 2018
Refusal Processed By Mpu
Sep 12, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Sep 11, 2018
Non-Final Action Written
Sep 6, 2018
Assigned To Examiner
Aug 30, 2018
Assigned To Examiner
Aug 29, 2018
Non-Final Action (Ib Refusal) Withdrawn For Review
Aug 27, 2018
Assigned To Examiner
Aug 22, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Aug 21, 2018
Non-Final Action Written
Aug 14, 2018
Assigned To Examiner
Jul 28, 2018
Application Filing Receipt Mailed
Jul 24, 2018
New Application Office Supplied Data Entered In Tram
Jul 19, 2018
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
